Results 111 to 120 of about 2,566,443 (193)

Effects of adding urinary alkalizer citrate mixture to febuxostat in gout patients with combined-type hyperuricemia and low urine pH: a prospective cohort study

Arthritis Research & Therapy
Background People with gout and combined-type hyperuricemia, defined as renal urate overload and renal urate under-excretion, have diminished responsiveness to urate-lowering therapy.
Kai Guo, Changgui Li, Robert Terkeltaub, Nicola Dalbeth, Xuefeng Wang, Xiaopeng Ji, Ying Chen, Lingling Cui, Zhen Liu, Xinde Li, Yuwei He, Jie Lu, Wenyan Sun, Lin Han, Hui Zhang, Aichang Ji, Mingshu Sun, Can Wang   +17 more
doaj   +1 more source

The experiences and perspectives of people with gout on urate self‐monitoring

Health Expectations
Introduction Gout management remains suboptimal despite safe and effective urate‐lowering therapy. Self‐monitoring of urate may improve gout management, however, the acceptability of urate self‐monitoring by people with gout is unknown.
Toni J. F. Michael, Jian S. Chan, Stephen Hughes, Daniel F. B. Wright, Matthew J. Coleshill, Dyfrig A. Hughes, Richard O. Day, Parisa Aslani, Sophie L. Stocker   +8 more
doaj   +1 more source

Surprising safety outcomes of urate-lowering therapy [PDF]

Nature Reviews Rheumatology, 2018
openaire   +2 more sources

The Uric Acid Dilemma: A Nutritional Odyssey

Annals of Rheumatology and Autoimmunity
Gout prevalence continues to rise worldwide, with an estimated 53.9 million cases in 2019, representing a 22% increase in age-standardized prevalence compared to 1990. Although urate-lowering pharmacotherapy remains the cornerstone of management, dietary
Muhammed Jasim Abdul Jalal
doaj   +1 more source

Initiation of Urate Lowering Therapy (ULT)

The Singapore Family Physician, 2019
Meng Kam Richard Lee, Yee Nah Anita Lim
openaire   +2 more sources

Can Urate Lowering Therapy Be Stopped in Gout? Rationale and Design of Two Large Randomised Trials

Lifelong urate-lowering therapy (ULT) is recommended for gout to prevent flares and urate deposition. However, concerns about its adherence, long-term side effects, and the necessity of continuous treatment after achieving remission raise critical ...
Pascal Richette, Noortje van Herwaarden, Leo A. B. Joosten, Marcel Flendrie   +3 more
core   +1 more source

Expert consensus on urate‑lowering therapy for high‑risk hyperuricemia (2026 edition). [PDF]

Chin Med J (Engl)
Zhu X, Mo Y, Duan L, Qing Y, Dai L, Zhang Z, Zhao Y, Zou H.   +7 more
europepmc   +1 more source

Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study. [PDF]

Rheumatol Adv Pract, 2023
Veenstra F, Vriezekolk JE, van den Bemt BJF, Schers HJ, Sloot B, van den Ende CHM, van Herwaarden N, Flendrie M.   +7 more
europepmc   +1 more source

Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio-renal-metabolic risk modulation. [PDF]

Eur Heart J Cardiovasc Pharmacother
Borghi C, Fogacci F, Cicero AFG.
europepmc   +1 more source

Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. [PDF]

Br J Clin Pharmacol, 2022
Coleshill MJ, Day RO, Tam K, Kouhkamari M, Caillet V, Aung E, Kannangara DRW, Cronin P, Rodgers A, Stocker SL.   +9 more
europepmc   +1 more source